Fadraciclib is currently being evaluated in first-in-human studies in patients with advanced solid tumors (NCT02552953) and in combination with the BCL2 inhibitor, venetoclax, in patients with relapsed or refractory CLL (NCT03739554) and relapsed refractory AML or MDS (NCT04017546). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.